Ik J. Chung
Hwasun, Republic of Korea
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 40 publications
Fever exerts opposing effects on the binding affinities of two neutralizing monoclonal antibodies against Staphylococcal Enterotoxin B.
Journal: Journal of thermal biology
Published: October 24, 2024
Nivolumab Plus Chemotherapy versus Placebo Plus Chemotherapy in Korean Patients with HER2-Negative, Untreated, Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer: Subgroup Analysis of a Randomized, Multicenter, Double-Blind Phase 3 Trial (ATTRACTION-4).
Journal: Cancer research and treatment
Published: September 13, 2024
Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 12, 2024
Comparative Whole-Genome Sequencing Analysis of In-situ and Invasive Acral Lentiginous Melanoma: Markedly Increased Copy Number Gains of GAB2 , PAK1 , UCP2 , and CCND1 are Associated with Melanoma Invasion.
Journal: The American journal of surgical pathology
Published: June 25, 2024
Developmental self-reactivity determines pathogenic Tc17 differentiation potential of naive CD8+ T cells in murine models of inflammation.
Journal: Nature communications
Published: April 20, 2023
Benefits of Adjuvant Chemotherapy for Clinical T3-4N0 Rectal Cancer After Preoperative Chemoradiotherapy.
Journal: Chonnam medical journal
Published: November 01, 2022
Geriatric functional assessment for decision-making on adjuvant chemotherapy in older colon cancer patients.
Journal: The Korean journal of internal medicine
Published: July 14, 2021
PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 16, 2021
Correction to: MYO1D binds with kinase domain of the EGFR family to anchor them to plasma membrane before their activation and contributes carcinogenesis.
Journal: Oncogene
Published: April 22, 2021
New strategy for suppressing the growth of lung cancer cells harboring mutations in the ATP-binding region of EGFR by targeting the molecular motor MYO1D.
Journal: Clinical and translational medicine
Published: February 22, 2021
Corrigendum to 'Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer', [Eur J Canc 51 (2015) 482-488].
Journal: European journal of cancer (Oxford, England : 1990)
Published: February 22, 2021
Last Updated: 09/26/2026